CT45A1: A Drug Target / Disease Biomarker (G541466)

Target Name: CT45A1

NCBI ID: G541466

CT45A1

CT45A1: A Drug Target / Disease Biomarker

CT45A1 is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and intestines. It is a member of the cryptocytosis family of proteins, which are involved in the intracellular transport of various molecules, including small molecules, ions, and vesicles.

One of the unique features of CT45A1 is its ability to interact with the protein known as EGFR, which is a transmembrane receptor that is involved in the regulation of cell growth, division, and survival. This interaction between CT45A1 and EGFR has led to the potential of CT45A1 as a drug target for various diseases, including cancer.

EGFR is a popular target for cancer because it is involved in the regulation of many different signaling pathways that promote cell growth and survival. Activation of EGFR can lead to increased cell proliferation, migration, and invasion, which can contribute to the development and progression of many types of cancer.

In addition to its role in cancer, CT45A1 has also been shown to be involved in the regulation of other important cellular processes. For example, it has been shown to play a role in the intracellular transport of neurotransmitters, which are chemical messengers that are used by the brain to communicate with other cells and tissues.

This involvement in neurotransmitter transport makes CT45A1 an interesting candidate as a drug target for disorders such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

Another potential application of CT45A1 as a drug target is its role in the regulation of inflammation. CT45A1 has been shown to play a role in the production and recruitment of immune cells to the site of inflammation, which suggests that it may be involved in the regulation of the immune response.

This involvement in immune regulation makes CT45A1 an interesting candidate as a drug target for diseases such as rheumatoid arthritis, inflammatory bowel disease, and other inflammatory conditions.

In addition to its potential as a drug target, CT45A1 is also a potential biomarker for various diseases. Its expression has been shown to be elevated in a variety of cancer types, as well as in diseases such as neurodegenerative conditions and immune disorders.

This suggests that CT45A1 may be a useful biomarker for the diagnosis and treatment of these diseases. Additionally, because it is involved in the regulation of multiple cellular processes, CT45A1 may also be a useful target for small molecules and other drugs that are used to treat a wide range of diseases.

Overall, CT45A1 is a protein that has the potential to be a drug target for a wide range of diseases. Its ability to interact with the protein known as EGFR and its involvement in the regulation of various cellular processes make it an interesting candidate for drug development. Additionally, its potential as a biomarker for diseases and its involvement in the immune response make it a promising target for small molecules and other drugs that are used to treat a wide range of diseases.

Protein Name: Cancer/testis Antigen Family 45 Member A1

The "CT45A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT45A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets